Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.
Advance ZincTek reports steady profit before tax for H1 FY25, driven by strong North American growth and significant cost savings following its Perth facility closure.